Results 11 to 20 of about 8,708 (251)

Pharmacokinetics of continuous infusion ceftolozane/tazobactam in two patients with extensive total body surface area burns

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 45, Issue 6, Page 386-392, June 2025.
Abstract Introduction Treatment of infections in patients with burn injuries is challenging due to altered antimicrobial pharmacokinetics. Continuous infusion β‐lactam therapy may be a useful antimicrobial stewardship strategy to improve pharmacodynamic target attainment in this population.
Jay D. Olivet, Megan Amerson‐Brown, Juan J. Calix, Emma Graffice, Tyson Kilpatrick, Hanna F. Roenfanz, David P. Nicolau, Joseph L. Kuti, Matthew L. Brown   +8 more
wiley   +2 more sources

Collateral susceptibility-guided alternation of ceftolozane/tazobactam with imipenem prevents resistance development in XDR Pseudomonas aeruginosa biofilms

Biofilm
Objectives: New combinations of β-lactams and β-lactamase inhibitors, such as ceftolozane/tazobactam could be useful to combat biofilm-driven chronic infections by extensively resistant (XDR) Pseudomonas aeruginosa but resistance development by mutations
María Fernández-Billón, Elena Jordana-Lluch, Aina E. Llambías-Cabot, María A. Gomis-Font, Pablo Fraile-Ribot, Rosa I. Torrandell, Pamela J. Colman-Vega, Óscar Murillo, María D. Macià, Antonio Oliver   +9 more
doaj   +2 more sources

Antibiotic Susceptibility of Aerobic and Facultative Anaerobic Gram-Negative Rods in Hong Kong and Implications on Usefulness of Ceftazidime-Avibactam and Ceftolozane-Tazobactam

Antibiotics
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years.
Jade L. L. Teng, Elaine Chan, Tsz Tuen Li, Tsz Ying Kwan, Ka Fai Chan, Wing Ho Li, Viki W. K. Tang, Man Lung Yeung, Susanna K. P. Lau, Patrick C. Y. Woo   +9 more
doaj   +2 more sources

Assessment of in vitro antimicrobial activities of ceftolozane/tazobactam and ceftazidime/avibactam against carbapenem-resistant Pseudomonas aeruginosa clinical isolates

BMC Infectious Diseases
Background Carbapenem resistant Pseudomonas aeruginosa (P. aeruginosa) is a global health concern that poses a challenge to treat in health care facilities.
Dalia Salem, Ahmed El-Shenawy, Heba Dahroug, Manar Zaiton, Doaa Gamal, Manal Diab   +5 more
doaj   +2 more sources

Physicochemical Compatibility of Ceftolozane-Tazobactam with Parenteral Nutrition

Pharmaceuticals
Ceftolozane-tazobactam (CT) is used for the treatment of complicated infections and for multidrug-resistant strains of Pseudomonas aeruginosa and extended-spectrum beta-lactamase-producing enterobacteria. In certain cases, simultaneous administration of CT and parenteral nutrition (PN) may be required, but compatibility of Y-site co-administration is ...
Jan Thomas De Pourcq, Adria Riera, Laura Gras, Noe Garin, Maria Antònia Busquets, Joana Cardenete, Daniel Cardona, Pau Riera   +7 more
openaire   +5 more sources

Activity of ceftolozane/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART – Brazil), 2018‒2021

Brazilian Journal of Infectious Diseases
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators ...
Amanda Azevedo Bittencourt, Vinicius Lima Faustino, Paula de Mendonça Batista, Lays Paulino Leonel, Marina Della Negra de Paula, Thales José Polis   +5 more
doaj   +2 more sources

Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales? [PDF]

Antimicrob Agents Chemother
Ceftolozane/tazobactam is widely used against extended-spectrum β-lactamase (ESBL)-producing Enterobacterales, yet FDA-approved dosing relies on intermittent infusion and a fixed 2:1 ratio that assumes adequate β-lactamase inhibition. Tazobactam’s faster
Pai MP, Cojutti PG, Gatti M, Rinaldi M, Tonetti T, Siniscalchi A, Viale P, Pea F.   +7 more
europepmc   +2 more sources

The new fifth-generation cephalosporins – a balance between safety and efficacy [PDF]

Romanian Journal of Pharmaceutical Practice, 2020
Cephalosporins are beta-lactam antibiotics classified into five generations. The newest generation has three representatives: ceftaroline fosamile, the combination ceftolozane/tazobactam (cephalosporin/beta-lactamase inhibitor), and ceftobiprole ...
Aura Rusu, Ioana-Andreea Lungu
doaj   +1 more source

Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study

Journal of Infection and Public Health, 2022
Background: Ceftolozane-tazobactam is an emerging ‎treatment for severe infections caused by multidrug-resistant (MDR) Pseudomonas ‎aeruginosa. However, limited ‎data support its use in bacteremia treatment.
Hakeam A. Hakeam, Ghadi Askar, Khalid Al Sulaiman, Reem Mansour, Maha M. Al Qahtani, Dana Abbara, Nada Aldhayyan, Nariman Dyab, Liyan Afaneh, Muna Islami, Zainab Al Duhailib   +10 more
doaj   +1 more source

Finding the Dose for Ceftolozane-Tazobactam in Critically Ill Children with and without Acute Kidney Injury

Antibiotics, 2020
Background: Ceftolozane-tazobactam is a new antibiotic against multidrug-resistant pathogens such as Pseudomonas aeruginosas. Ceftolozane-tazobactam dosage is still uncertain in children, especially in those with renal impairment or undergoing continuous
Laura Butragueño-Laiseca, Iñaki F. Troconiz, Santiago Grau, Nuria Campillo, Xandra García, Belén Padilla, Sarah N. Fernández, María José Santiago   +7 more
doaj   +1 more source